{
      "Rank": 688,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "10 \u03bcg/kg/day of Filgrastim will be given subcutaneously for 4 days"
      ],
      "ArmGroupInterventionName": [
            "Drug: Filgrastim"
      ],
      "ArmGroupLabel": [
            "Melanoma, head and neck"
      ],
      "ArmGroupType": [
            "Other"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02331134"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The overall goal of this study is to develop a pre-clinical platform of melanoma and head and neck squamous cell cancer that will allow the investigators to learn more about these diseases and discover better and more individualized treatments."
      ],
      "BriefTitle": [
            "Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer"
      ],
      "CentralContactEMail": [
            "meaghan.greb@cuanschutz.edu",
            "cole.sprague@cuanschutz.edu"
      ],
      "CentralContactName": [
            "Meaghan Greb",
            "Cole Sprague"
      ],
      "CentralContactPhone": [
            "720-848-0657",
            "720-848-8030"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "UNKNOWN"
      ],
      "CollaboratorName": [
            "Karsh Family Research Fund"
      ],
      "CompletionDate": [
            "March 2023"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Malignant Melanoma",
            "Head and Neck Cancer"
      ],
      "ConditionAncestorId": [
            "D000018358",
            "D000017599",
            "D000009373",
            "D000009370",
            "D000009369",
            "D000009380",
            "D000018326",
            "D000009371"
      ],
      "ConditionAncestorTerm": [
            "Neuroendocrine Tumors",
            "Neuroectodermal Tumors",
            "Neoplasms, Germ Cell and Embryonal",
            "Neoplasms by Histologic Type",
            "Neoplasms",
            "Neoplasms, Nerve Tissue",
            "Nevi and Melanomas",
            "Neoplasms by Site"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC04",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Neoplasms",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Melanoma",
            "Head and Neck Cancer"
      ],
      "ConditionBrowseLeafId": [
            "M10680",
            "M8500",
            "M19648",
            "M18997",
            "M19540",
            "M11470",
            "M11467",
            "M11477",
            "M11598",
            "M11600",
            "M19623",
            "T4091",
            "T4092"
      ],
      "ConditionBrowseLeafName": [
            "Melanoma",
            "Head and Neck Neoplasms",
            "Neuroendocrine Tumors",
            "Neuroectodermal Tumors",
            "Neuroectodermal Tumors, Primitive",
            "Neoplasms, Germ Cell and Embryonal",
            "Neoplasms by Histologic Type",
            "Neoplasms, Nerve Tissue",
            "Nevus",
            "Nevus, Pigmented",
            "Nevi and Melanomas",
            "Neuroendocrine Tumor",
            "Neuroepithelioma"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000008545",
            "D000006258"
      ],
      "ConditionMeshTerm": [
            "Melanoma",
            "Head and Neck Neoplasms"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Basic Science"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "The main objective of this study is to establish a humanized animal model. Investigators will consent patients who have melanoma and head and neck squamous cell cancer (HNSCC) and agree to take part in this research study. They will obtain peripheral hematopoietic stem cells (HSC), blood and tumor tissue at baseline from blood and tumor samples from these patients for use in establishing tumor explants in humanized mice. Therapy results on humanized mice will be correlated with existing or newly acquired efficacy results from those same immune-based or other therapies in patients. A secondary objective is to identify pharmacodynamic markers associated with each drug and biomarkers for evidence of efficacy or lack of thereof. Where possible, subjects receiving therapy with FDA-approved drugs of interest will be asked to provide sequential blood and tumor biopsies to study the molecular and immune events that may occur as a result of drug therapy."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nBiopsy proven incurable melanoma or incurable HNSCC amenable to have biopsy and/or surgical resection of either the primary and/or locoregional metastatic site, at the University of Colorado Hospital.\nAge \u2265 21 years old per NCI/NIH guidelines\nEastern Cooperative Oncology Group (ECOG) performance status of 0. 1, or 2\n\nAdequate bone marrow, hepatic and renal function:\n\nAbsolute neutrophil count \u2265 1,500/\u00b5L.\nPlatelets \u2265 100,000/\u00b5L.\nHemoglobin \u2265 9.0 g/dL.\nCreatinine \u2264 1.5x upper limit of normal (ULN) or calculated creatinine clearance \u2265 60 mL/min.\nTotal bilirubin \u2264 1.5x ULN.\nAspartate Aminotransferase (AST)/Alanine Aminotransferase ( ALT) \u2264 2x ULN.\nMeasurable disease according to Response Criteria in Solid Tumors (RECIST) version 1.1.\nO2 saturation \u2265= 93% at room air.\nAbility to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\nContraindication (absolute or relative) to granulocyte colony-stimulating factor (G-CSF) filgrastim usage:\n\nknown hypersensitivity to E coli-derived proteins' filgrastim, or any other component of the product.\nSickle cell disorders.\nClinically significant and active lung hemorrhagic or inflammatory disease, including but not limited to chronic obstructive pulmonary disease (COPD), autoimmune disease, and alveolar hemorrhage; or hypoxemia of any etiology requiring oxygen.\nClinically significant splenomegaly or splenic metastases; history of splenic rupture, recent splenic trauma or other clinically significant splenic disease that increases the risk of splenic rupture.\nClinically significant and active malignancy other than incurable melanoma or head and neck squamous cell cancer.\nKnown hepatitis B or C, or HIV."
      ],
      "EnrollmentCount": [
            "40"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000276",
            "D000007155",
            "D000045505"
      ],
      "InterventionAncestorTerm": [
            "Adjuvants, Immunologic",
            "Immunologic Factors",
            "Physiological Effects of Drugs"
      ],
      "InterventionArmGroupLabel": [
            "Melanoma, head and neck"
      ],
      "InterventionBrowseBranchAbbrev": [
            "All"
      ],
      "InterventionBrowseBranchName": [
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Long-"
      ],
      "InterventionBrowseLeafId": [
            "M1945",
            "M2780",
            "M9353"
      ],
      "InterventionBrowseLeafName": [
            "Lenograstim",
            "Adjuvants, Immunologic",
            "Immunologic Factors"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Patients will receive 10 \u03bcg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule"
      ],
      "InterventionMeshId": [
            "D000078224"
      ],
      "InterventionMeshTerm": [
            "Lenograstim"
      ],
      "InterventionName": [
            "Filgrastim"
      ],
      "InterventionOtherName": [
            "Neupogen"
      ],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Tissue",
            "Hematopoietic Stem Cell",
            "Melanoma",
            "Squamous Head and Neck Cancer"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "June 22, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "June 20, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "University of Colorado, Denver"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Aurora"
      ],
      "LocationContactEMail": [
            "meaghan.greb@cuanschutz.edu"
      ],
      "LocationContactName": [
            "Meaghan Greb"
      ],
      "LocationContactPhone": [
            "303-848-0657"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact"
      ],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "University of Colorado Cancer Center"
      ],
      "LocationState": [
            "Colorado"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "80045"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Pilot Study of Tissue and Hematopoietic/Mesenchymal Stem Cell Collection for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of Colorado, Denver"
      ],
      "OrgStudyId": [
            "14-0842.cc"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "University of Colorado, Denver"
      ],
      "OverallOfficialName": [
            "Antonio Jimeno, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Not Applicable"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "February 2023"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Tissue and hematopoietic/mesenchymal stem cell will be collected from patients with melanoma and squamous head and neck cancer. These will be used to establish humanized animal model."
      ],
      "PrimaryOutcomeMeasure": [
            "Tissue and Hematopoietic Stem Cell Collection"
      ],
      "PrimaryOutcomeTimeFrame": [
            "At the time of sample collection"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Patients receiving therapy with Food and Drug Administration (FDA) approved drugs of interest will be asked to provide sequential blood and tumor biopsies to study the molecular and immune events occurring as a result of therapy"
      ],
      "SecondaryOutcomeMeasure": [
            "Identify pharmacodynamic markers"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Up to 6 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 13, 2015"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "June 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "January 6, 2015"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "December 26, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "December 26, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}